Gene: LRRN2

10446
FIGLER7|GAC1|LRANK1|LRRN5
leucine rich repeat neuronal 2
protein-coding
1q32.1
Ensembl:ENSG00000170382 MIM:605492 Vega:OTTHUMG00000035989 UniprotKB:O75325
NC_000001.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.435e-1 (AD)  6.371e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11801229chr1:204645347 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMEM250.903
ANKRD34A0.895
CELF50.892
PRRT30.892
DISP20.891
PGBD50.889
SLC8A20.889
TBC1D250.887
SPTBN40.887
CELSR20.887

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
REST-0.552
TFPI2-0.546
YES1-0.535
WWTR1-0.535
GNG11-0.515
RAI14-0.511
IL18RAP-0.493
CNN2-0.492
WEE1-0.492
COPZ2-0.487

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of LRRN2 mRNA"27291303
D000082AcetaminophenAcetaminophen results in decreased expression of LRRN2 mRNA22230336
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of LRRN2 mRNA21298039
D001151ArsenicArsenic affects the methylation of LRRN2 gene25304211
C006780bisphenol Abisphenol A results in decreased expression of LRRN2 mRNA27685785
C006780bisphenol Abisphenol A results in decreased expression of LRRN2 mRNA25181051
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LRRN2 gene20938992
D016572CyclosporineCyclosporine results in decreased expression of LRRN2 mRNA27989131
D003561CytarabineCytarabine results in decreased expression of LRRN2 mRNA21198554
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LRRN2 gene20938992
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of LRRN2 gene20938992
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of LRRN2 mRNA19710929
D011374ProgesteroneProgesterone results in decreased expression of LRRN2 mRNA20631399
D011374ProgesteroneProgesterone results in increased expression of LRRN2 mRNA23018184
D012999SomanSoman results in decreased expression of LRRN2 mRNA19281266
D014635Valproic AcidValproic Acid results in decreased expression of LRRN2 mRNA29154799
D014635Valproic AcidValproic Acid results in increased methylation of LRRN2 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of LRRN2 gene25560391
C025643vinclozolinvinclozolin results in decreased expression of LRRN2 mRNA23034163

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0038023signaling receptor activity-TAS9662332  
GO ID GO Term Qualifier Evidence PubMed
GO:0007155cell adhesion-TAS9662332  
GO:0007165signal transduction-TAS9662332  
GO ID GO Term Qualifier Evidence PubMed
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal